相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Narendra Chirmule et al.
AAPS JOURNAL (2012)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors
Devesh Mewar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development
Alvydas Mikulskis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Differential effect of drug interference in immunogenicity assays
Margreet H. Hart et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Use of biological molecules in the treatment of inflammatory bowel disease
O. H. Nielsen et al.
JOURNAL OF INTERNAL MEDICINE (2011)
What's fueling the biotech engine-2010 to 2011
Saurabh Aggarwal
NATURE BIOTECHNOLOGY (2011)
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
Dora Pascual-Salcedo et al.
RHEUMATOLOGY (2011)
Bioanalytical interferences in immunoassays for antibody biotherapeutics
Charles Pendley et al.
BIOANALYSIS (2011)
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
A. Vultaggio et al.
ALLERGY (2010)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases
Nadia Emi Aikawa et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2010)
Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia
W. Connell et al.
INTERNAL MEDICINE JOURNAL (2010)
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease
W. Miehsler et al.
JOURNAL OF CROHNS & COLITIS (2010)
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals hidden immunogenicity in rheumatoid arthritis patients
Pauline A. van Schouwenburg et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy
D. Dimichele
HAEMOPHILIA (2009)
Durability of Infliximab in Crohn's Disease: A Single-Center Experience
Jason E. Gonzaga et al.
INFLAMMATORY BOWEL DISEASES (2009)
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
Klaus Bendtzen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore
Denise Sickert et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
Eugen Koren et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
Gopi Shankar et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA
Holly W. Smith et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2007)
Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance
Baodong Sun et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Immunogenicity of protein therapeutics
Anne S. De Groot et al.
TRENDS IN IMMUNOLOGY (2007)
Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin
Rebecca Howman et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen
A Patton et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks
IC Macdougall
NEPHROLOGY DIALYSIS TRANSPLANTATION (2005)
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
AR Mire-Sluis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab
E Miele et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2004)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)